Meet Remi

Remi: AI built for cancer care, not adapted to it

Remi is Cureety’s conversational assistant for patients between visits. Patients describe how they feel in their own words, by text. Remi structures what they share and brings in our oncology-trained clinicians when a situation needs human attention.

The conversational layer

Just a text message away, 24/7

No app, no portal, no password. Patients reach Remi by text message, at any hour. Your team or our Cureety Care Team receives structured information, not a stream of messages.

Natural conversations

Patients answer in plain language. Remi understands free text and asks follow-up questions to clarify.

Human handoff

When a patient needs a clinician, Remi hands off to our Virtual Care Center with the full context already captured.

Proactive check-ins

Remi reaches out on a schedule your team defines, so symptoms surface before the next visit.

Protocol-based routing

Remi follows evidence-based protocols, configured with your team, to route each report to the right level of care.

Reviewed education

Remi shares medically reviewed content matched to each patient’s symptoms and treatment.

Compare Remi

Oncology AI vs. general-purpose chatbots

Specialized AI with human oversight

Remi

Built for oncology

Every conversation runs within clinical protocols, with oncology nurses ready to take over.

Generic AI 

General-purpose AI

Built for everything

No clinical protocol, no clinician behind the answer. Subjective questions, uncertain outputs.

AI with human oversight

The same symptom does not always carry the same risk

Grade 1 dyspnea

Patient on Pembrolizumab

Low-risk signal

Grade 1 dyspnea

Patient on Trastuzumab Deruxtecan

ILD Risk

A patient with Grade 1 dyspnea on Pembrolizumab may not have a high risk. The same symptom in a patient receiving Trastuzumab Deruxtecan could indicate a high risk of interstitial lung disease. Cureety's intelligence layer ensures triage is aligned with the regimen's toxicity profile.

Over 1 million questionnaires completed · validated algorithm with 94.4% specificity and 95.8% sensitivity for critical classifications. {tooltip} Positea-va study. The algorithm correctly identifies 95.8% of patients classified as "critical" by experts. Only 5.6% false positives.Peer-reviewed and validated over 400 patients. {a:https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.1605}Source{/a}{/tooltip}